Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
Kelley longed for a normal life, to go to college, to have normal friends, and to work a nice desk job. When an unknown predator starts a killing spree, she finds herself drug back into a world that includes vampires, werewolves, and her ex-husband. Find out more at http://saramdrake0.blogspot.com/. Family Heir: A Bigfoot Novel by Sara M. Drake book trailer. Paranormal/Urban Fantasy
Estado de gracia, la serie dramática de ficción sobre el narcotráfico que aborda por primera vez el polémico tema de la legalización de las drogas en México, se estrena el lunes 4 de junio, en exclusiva a través de Cinelatino, el canal líder de películas en español en Estados Unidos. La serie que cuenta con altos estándares de producción no se ha visto en ningún otro país en el mundo.
Esta producción mexicana es un thriller de suspenso político que presenta un retrato realista sobre el fenómeno del narcotráfico en México, que arroja luz sobre la red de dinero, el poder y la corrupción que alimenta el negocio ilícito de las drogas.
Para más, va a http://www.multivu.com/mnr/56310-cinelatino-estado-de-gracia-mexico-drug-trade-legalization?lang=es
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Astellas Pharma Europe Ltd. today presented The Economist Innovation 2011 award for Bioscience to one of the world’s most influential biomedical engineers, Dr Robert Langer – the man responsible for founding the field of controlled-release drug delivery and tissue engineering.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellaspharma/52158/
Vikes, Dance Fever, French Fries. The names might not be familiar to you, but chances are good your kids have heard of them. These are the street names for prescription drugs, and more and more teens are using them to get high.
Each year, nearly 2 million teens abuse prescription drugs. The new parent’s Prescription and Over-the-Counter Drug Guide from BeSmartBeWell.com and The Partnership at Drugfree.org breaks down the most commonly abused prescription and over-the-counter drugs in a simple-to-understand and interactive web page. Learn drugs’ “street” names, how kids are using them (inject, inhale, etc.), why they're dangerous and the warning signs of abuse.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/besmartbewell/50821/
HealthCare Partners, a division of DaVita Inc. (NYSE: DVA), a leading independent medical group in the United States, is encouraging Medicare beneficiaries to review their health care coverage during Medicare’s Open Enrollment Period.
From October 15 through December 7, Medicare holds its annual Open Enrollment Period. During this seven-week window, Medicare beneficiaries can make changes to their health and prescription drug plans for the following year.
If you are satisfied with your Medicare coverage, you may wonder how open enrollment applies to you. As the old adage goes, “if it isn’t broke, don’t fix it,” right?
While this may certainly be the case for many things in life, it may not be true about your Medicare coverage. Choosing a Medicare plan is similar to shopping for other insurance; by comparing different plans and rates, you choose the coverage that’s best for you.
To view the multimedia release go to:
http://www.multivu.com/players/English/7920151-healthcare-partners-medicare-open-enrollment/
As the rate of teen prescription drug abuse continues to rise in the United States, the National Association of School Nurses (NASN) and Janssen Pharmaceuticals, Inc., today joined with addiction expert Dr. Drew Pinsky,* to launch a new tool kit intended to help America’s schools educate teens and their parents about the risks and consequences of abusing prescription medication.
The Schools Get Smart, Schools Take Action Tool Kit is part of Smart Moves, Smart Choices, a national initiative of NASN and Janssen Pharmaceuticals, Inc., designed to inform parents, teens and educators about this growing problem of teen prescription drug abuse, and what they can do to combat it.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/smartmovessmartchoices/51444/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
ILEX Consumer Products Group, a Baltimore-based company which owns and manages health and beauty as well as over the counter (OTC) drug brands, launched di-gel, a new antacid/anti-gas brand, just in time for all the overindulging and stress of the holidays.
The new digestive aid, which is being promoted with integrated TV and digital advertising, grassroots and public relations, launched with the brand tagline
